NDT Advance Access originally published online on December 29, 2005
Nephrology Dialysis Transplantation 2006 21(4):991-998; doi:10.1093/ndt/gfk011
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Original Articles: Dialysis and Transplantation
Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients
1 Department of Nephrology and Dialysis, Ospedale A. Manzoni, Lecco, 2 Department of Nephrology, Università di Napoli Federico II, Naples, 3 Department of Nephrology and Dialysis, ‘Spedali Civili’, Brescia, 4 Department of Nephrology and Dialysis, Ospedale ‘Misericordia e Dolce’, Prato, 5 Department of Nephrology, Azienda Ospedaliera ‘G.Moscati’, Avellino and 6 U.O. Nefrologia, CNR - I.B.I.M., Ospedali Riuniti Reggio Calabria, Italy
Correspondence and offprint requests to: Prof. Francesco Locatelli Department of Nephrology and Dialysis, Ospedale A. Manzoni, Via dell’Eremo 9, 23900 Lecco, Italy. Email: nefrologia{at}ospedale.lecco.it
Background. Chronic kidney disease patients who are resistant to erythropoietin (EPO) treatment may suffer from malnutrition and/or inflammation.
Methods. In a cross-sectional study of haemodialysis patients, we investigated the relationship between the natural logarithm of the weekly EPO dose normalized for post-dialysis body weight and outcome measures of nutrition and/or inflammation [BMI, albumin and C reactive protein (CRP)] by means of multiple linear regression analysis. On the basis of the decile distribution of weekly EPO doses, we also evaluated four groups of patients: untreated, hyper-responders, normo-responders and hypo-responders.
Results. Six hundred and seventy-seven adult haemodialysis patients were recruited from five Italian centres. BMI and albumin were lower in the hypo-responders than in the other groups (21.3±3.8 vs 24.4±4.7 kg/m2, P<0.001; and 3.8±0.6 vs 4.1±0.4 g/dl, P<0.001), whereas the median CRP level was higher (1.9 vs 0.8 mg/dl, P = 0.004). The median weekly EPO dose ranged from 30 IU/kg/week in the hyper-responsive group to 263 IU/kg/week in the hypo-responsive group. Transferrin saturation linearly decreased from the hyper- to hypo-responsive group (37±15 to 25±10%, P = 0.003), without any differences in transferrin levels. Ferritin levels were lower in the hypo-responsive than in the other patients (median 318 vs 445 ng/ml, P = 0.01). At multiple linear regression analysis, haemoglobin, BMI, albumin, CRP and serum iron levels were independently associated with the natural logarithm of the weekly EPO dose (R2 = 0.22).
Conclusions. Our findings support a clear association between EPO responsiveness and nutritional and inflammation variables in haemodialysis patients; iron deficiency is still a major cause of hypo-responsiveness.
Keywords: albumin; C reactive protein; EPO resistance; haemodialysis; inflammation; malnutrition
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Wystrychowski, T. M. Kitzler, S. Thijssen, L. Usvyat, P. Kotanko, and N. W. Levin Impact of switch of vascular access type on key clinical and laboratory parameters in chronic haemodialysis patients Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2194 - 2200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Singh, J. Himmelfarb, and L. A. Szczech Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia: Pro J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1436 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Bradbury, C. W. Critchlow, M. R. Weir, R. Stewart, M. Krishnan, and R. H. Hakim Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients Nephrol. Dial. Transplant., March 1, 2009; 24(3): 919 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. M. de Francisco Key insights into present and future treatments of anaemia in CKD patients NDT Plus, January 1, 2009; 2(suppl_1): i1 - i2. [Full Text] [PDF]
|
|
|
|
|
|
A. L. M. de Francisco, P. Stenvinkel, and S. Vaulont Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness NDT Plus, January 1, 2009; 2(suppl_1): i18 - i26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Agarwal, J. L. Davis, and L. Smith Serum Albumin Is Strongly Associated with Erythropoietin Sensitivity in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Girndt, P. Stenvinkel, C. Ulrich, J. Axelsson, L. Nordfors, P. Barany, J. J. Carrero, G. H. Heine, H. Kaul, and H. Kohler Influence of cytokine gene polymorphisms on erythropoetin dose requirements in chronic haemodialysis patients Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3586 - 3592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M.C. Brunini, A. C. Mendes-Ribeiro, J. C. Ellory, and G. E. Mann Platelet nitric oxide synthesis in uremia and malnutrition: A role for L-arginine supplementation in vascular protection? Cardiovasc Res, January 15, 2007; 73(2): 359 - 367. [Abstract] [Full Text] [PDF]
|
|